** Shares of medical diagnostics co Lantheus Holdings LNTH.O fall 7.4% to $91.03
** LNTH says it will buy Evergreen Theragnostics to expand its oncology radiopharmaceutical pipeline with multiple experimental cancer treatments
** Deal consists of an upfront payment of $250 mln and up to $752.5 mln in milestone payments to Evergreen
** JonesTrading analyst Justin Walsh says current weakness in LNTH is due to concerns about the co deploying cash on acquisitions that are expected to add to EPS only ~18 months post-close; he believes this market reaction is "wholly unwarranted"
** Deal expected to close in H2 2025
** 12 of 13 brokerages rate the stock "buy" or higher and 1 "hold"; their median PT is $135 - LSEG
** LNTH gained 41.8% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。